Clinical trial
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in…
NCT00240695 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00240695 |
|---|---|
| Title | A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment |
| Official title | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases |
| Intervention type | Drug |
| Interventions | galantamine hydrobromide |
| Enrollment | 724 |
| Start date | May 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Oct 18, 2005 |
| Last update posted | May 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: